![](https://webarchive.library.unt.edu/eot2008/20080922033533im_/http://www.nci.nih.gov/images/spacer.gif) |
|
Myeloproliferative Disorders Trial Results
1. Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia (Posted: 03/27/2007) - Low doses of the chemotherapy drug cytarabine increased overall survival in patients with acute myeloid leukemia who were not healthy enough to receive the standard treatment of high-dose, intensive chemotherapy, according to the March 15, 2007, issue of the journal Cancer.
![](https://webarchive.library.unt.edu/eot2008/20080922033533im_/http://www.nci.nih.gov/images/spacer.gif)
2. Lenalidomide Reduces Need for Blood Transfusions in Myelodysplastic Syndrome (Posted: 05/15/2005) - Lenalidomide (Revlimid) reduced the need for blood transfusions in some patients with myelodysplastic syndrome (MDS), according to findings presented at the 2005 meeting of the American Society of Clinical Oncology.
|
|
![](https://webarchive.library.unt.edu/eot2008/20080922033533im_/http://www.nci.nih.gov/images/spacer.gif) |